Blood Pressure Drug Misses in Phase III, Aims for New Target

Chelsea Therapeutics is shifting gears with a drug candidate intended for Parkinson’s disease patients, now choosing to focus on a new target after the compound missed its primary goal in late stage clinical trials.
MedCity News